Avacta Group aims to save lives by developing ground-breaking and affordable cancer treatments

The Yorkshire-based Avacta Group aims to save lives by developing ground-breaking and affordable cancer treatments.
By Greg Wright
Published 3rd Feb 2022, 07:37 BST
Updated 3rd Feb 2022, 07:40 BST

Avacta Group has announced that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the next dose cohort following a positive review of the safety data from the dosing of the first cohort.

The statement said: "Avacta’s Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has completed its review of the safety data from the first cohort dosed with AVA6000 at 80mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 120mg/m2.

Hide Ad
Hide Ad

"AVA6000 is a novel form of doxorubicin that has been modified with Avacta’s pre|CISION platform to improve its safety and therapeutic index. Anthracyclines such as doxorubicin, a generic chemotherapy with a market size that is expected to grow to $1.38bn by 2024, are widely used as part of standard of care in several tumour types, but their use is limited by cumulative toxicity.

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: “We are delighted with the SDMC’s recommendation to move on to the next dose of AVA6000 in our dose escalation study following its positive review of the safety data from patients in the first cohort."Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: “We are delighted with the SDMC’s recommendation to move on to the next dose of AVA6000 in our dose escalation study following its positive review of the safety data from patients in the first cohort."
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: “We are delighted with the SDMC’s recommendation to move on to the next dose of AVA6000 in our dose escalation study following its positive review of the safety data from patients in the first cohort."

"AVA6000 has been designed to limit cell penetration of the drug, and therefore its cell killing effect, until it is specifically activated by fibroblast activation protein α (FAP) which is in high concentration in many solid tumours compared with healthy tissues. The resulting reduced exposure of healthy tissues to active doxorubicin has the potential to significantly increase its therapeutic index by reducing the incidence of adverse effects, including cardiotoxicity and myelosuppression."

Read More
Wetherby drug developer's lateral flow tests shown to detect the Omicron variant

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: “We are delighted with the SDMC’s recommendation to move on to the next dose of AVA6000 in our dose escalation study following its positive review of the safety data from patients in the first cohort.

“We are very excited by the potential of AVA6000, and the pre|CISION platform more broadly, to deliver ground-breaking and affordable cancer treatments that have the potential to significantly improve patients’ lives.”

Hide Ad
Hide Ad

Last year, Avacta revealed it was to start a phase I study of its cancer drug, AVA6000, in a range of cancers to establish its safety, tolerability and effectiveness.

The Wetherby-based group received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a Clinical Trial Authorisation (CTA) in the UK for a phase I study of its lead pre|CISION pro-drug, AVA6000 pro-doxorubicin.

Related topics:Yorkshire